Table 1.
Demographics, clinical details of patients with thyroid autoimmunity and control subjects without autoimmune disease
| Control | Graves ophthalmopathy | Graves hyperthyroidism | Hashimoto’s thyroiditis |
|---|---|---|---|
| Age: 35.7±12.8 | Age: 52.4±14.6 | Age: 48.7±15.8 | Age: 51.8±15.3 |
| (N=148 28%) | (N=82, 15.5%) | (N=156, 29.5%) | (N=143, 27%) |
| Clinical parameter | |||
| Age at diagnosis | 43±14 (N=66) | 40±16 (N=116) | 39±17 (N=99) |
| Other autoimmune disorders | 7 (41%) | 11 (7%) | 17 (15%) |
| Family history of thyroid disorders | 24 (66%) | 77 (54%) | 57 (56%) |
| Isotope scan | 21 (40%) | 52 (71%) | |
| Goiter diffuse with 1–3 nodules | 23 (38%) | 29 (47%) | |
| 1 nodule | 10 (29%) | 19 (27%) | 49 (47%) |
| 2 nodules | 15 (44%) | 39 (56%) | 55 (53%) |
| Medication | 51 (60%) | 88 (61%) | 107 (92%) |
| Radioactive iodine treatment | 12 (14%) | 21 (14%) | |
| Surgery | 22 (26%) | 36 (25%) | |
| TRAB | 46.4±132 (N=30) | 65.5±160 (N=37) | |
| TPO (KIU/L) | 136±106 (N=6) | 752±876 (N=10) | 904±899 (N=62) |
| FT4 at diagnosis (pmol/L) | 37.7±23.7 (N=40) | 45.2±27.5 (N=74) | 12.2±6.1 (N=47) |
| FT3 at diagnosis (pmol/L) | 17.1±11.9 (N=32) | 35.8±124 (N=51) | 17.3±33.2 (N=6) |
| TSH (mu/L) | 25.39±41.06 95% confidence interval (16.26–34.53, N=80) |
||
| Highest TSH (mu/L) | 25.26±28.28, 95% confidence interval (14.07–36.44, N=27) |
||
| TG AB (KIU/L) | 169±286 (N=35) | ||
| Diagnosis <12/12 post-partum | N=20 | ||
| Hashitoxicosis | N=10 | ||
| Hashimoto’s did not require treatment | N=6 | ||
| Non-European | N=7 | N=32 | N=7 |
| Male | N=12 | N=30 | N=12 |
| Female | N=62 | N=101 | N=84 |
Notes: Age of population expressed as mean years ± standard deviation. Number of patients expressed as N, % of total population.
Abbreviations: AB, antibody; TRAB, thyroid receptors antibodies; TgAB, thyroglobulin antibodies; TPO, thyroid peroxidase; TSH, thyroid stimulating hormone; FT4, free tetraiodothyronine; FT3, free triiodothyronine.